Goracinova, Katerina
Preferred name
Goracinova, Katerina
Official Name
Goracinova, Katerina
Translated Name
Gorachinova, Katerina
Main Affiliation
Email
kago@ff.ukim.edu.mk
Researcher ID
H-8486-2013
10 results
Now showing 1 - 10 of 10
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Rational development of nanomedicines for molecular targeting in periodontal disease(Elsevier BV, 2018-09); ; Recent advances in understanding the etiology and pathogenesis of periodontal disease and polymicrobial synergy in the dysbiotic oral microbial community endorsed novel therapeutic targets and assured further improvement in periodontal disease treatment. Moreover, understanding of the events at the molecular level inspired the researchers to alleviate the stress from the disease by applying the bottom-up approach and delivering the drugs at the site of action, using nanoscale medicines. This review is focused on promising strategies for rational design of nanopaharmaceuticals for periodontal disease treatment based on novel therapeutic targets and the potential of advanced concepts for inflammation cascade targeting. Due to their size, nanomedicines are capable to interact with the elements of the immune system through cell receptor binding and to subsequently influence specific intracellular signaling pathways activation. They might also interfere with different signaling molecules continuously involved in the disease progression, in order to abolish cell activation and block the production of proinflammatory substances. Different biomacromolecules can be trafficked to the site of action using nanomedicines for gene targeting: i) decoy oligodeoxynucleotide (ODN) for suppression of NF-κB transcription activity, ii) DNA therapeutics for modulation of cell inflammatory response and iii) siRNA for cytokine production silencing. However, despite the potential of the nanotechnology for improvement of periodontal disease treatment, the translation of nano-drug delivery systems to clinical therapy is hindered by the lack of standard procedures for proper safety and efficacy profile evaluation. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 3D printed extended-release hydrochlorothiazide tablets(Elsevier BV, 2025-03-01); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Design and biological response of doxycycline loaded chitosan microparticles for periodontal disease treatment(Elsevier BV, 2018-04-15); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ORMOSIL nanoparticles as drug delivery carriers for oxaliplatin: formulation development and characterization(Springer Science and Business Media LLC, 2024-06-17); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Reduced Cardiotoxicity of Ponatinib-Loaded PLGA-PEG-PLGA Nanoparticles in Zebrafish Xenograft Model(MDPI, 2022-06-02) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer(BEILSTEIN INSTITUT, 2023-02-22) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Micro-Raman Spectroscopy for Detection of Label-Free and Oil Red O Labeled PEGylated Nanoliposomes in hCmec/D3 Cell Internalization Studies(Croatian Chemical Society, 2022-12); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The role of intellectual property rights and package safety features in the prevention of counterfeit medicines(Centre for Evaluation in Education and Science (CEON/CEES), 2020-12); ; ; Petrovska-Jakimovska, BiljanaThe fast growth of counterfeiting medicines in the last two decades has created one of the biggest problems facing the pharmaceutical industry on the global level, resulting in loss of income, product withdrawal, loss of brand value, etc. But this is not only the problem of the intellectual property rights of the pharmaceutical industry, it is also the problem of the healthcare regulatory authorities, whose most significant concern is the risk to the public health. Pharmaceutical manufacturers, together with the wholesalers and retailers, have an essential role in the fight against counterfeit medicines by the implementation of different anti-counterfeit technologies for securing the supply-chain of medicines. The protection of drug packaging has a specific role in the drug development process, as well as in the fight against counterfeit medicine. The authenticity of the medicine and the forensic elements for protection on the packaging may be confirmed using different technologies. Tracking and tracing of pharmaceutical products in the supply chain, keeping electronic records for all stages of the distribution, and verification of the authenticity of a medicinal product is a key element and an effective solution for timely detection of counterfeit medicines and protection of intellectual property rights. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparative Modeling Approaches in the Development and Evaluation of Silica Nanoparticles as 5-Fluorouracil Carriers using PLS, DoE and GBR(Springer Science and Business Media LLC, 2025-11-24); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparative Modeling Approaches in the Development and Evaluation of Silica Nanoparticles as 5-Fluorouracil Carriers using PLS, DoE and GBR(Springer Science and Business Media LLC, 2025-11-24); ;